Abstract:
Substituted benzenesulfonylureas and -thioureas of the formula I in which R1, R2, E, X, Y and Z have the meanings described herein, show effects on the autonomous nervous system. The invention relates to the use of the compounds of the formula I in the treatment and prophylaxis of dysfunctions of the autonomous nervous system, in particular of vagal dysfunctions, for example in the case of cardiovascular diseases. The invention also relates to the use of compounds of the formula I in combination with beta-receptor blockers and to products and pharmaceutical preparations which comprise at least one compound of the formula I and at least one beta-receptor blocker, and to novel compounds.
Abstract:
The present invention relates to hydroxymethylfurazancarboxylic acid derivatives of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents hydroxymethyl and the other represents ##STR2## where X represents NR.sup.3 R.sup.4, OH or OR.sup.7, and R.sup.3, R.sup.4 and R.sup.7 are defined as indicated in claim 1, to processes for their preparation and to their use.
Abstract:
The present invention relates to phenylfuroxans of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents phenyl and the other represents ##STR2## where R.sup.3, R.sup.4 and n are defined as indicated in claim 1, processes for their preparation and their use.
Abstract:
Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sup.1 denotes e.g. hydrogen;R.sup.2 denotes e.g. an alkyl radical;at least two of the radicals R.sup.3, R.sup.4, R.sup.5 and R.sup.6 denote alkyl radicals and the others denote hydrogen, are prepared by cyclization of a compound of the formula II ##STR2## and, if appropriate, subsequent acylation, and have useful pharmacological properties.
Abstract:
Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes, for example, --CH.sub.2 --,R.sup.1 denotes hydrogen or the radical --COR.sup.5,R.sup.2, R.sup.3 denote alkyl having 1 to 4 C atoms,R.sup.5 denotes, for example, an aliphatic radical having 1 to 4 C atoms,and methods for preparing such compounds by cyclization of a compound of the formula II ##STR2## and if desired subsequent acylation. The invention also includes formulations containing effective amounts of such compounds, and methods for administering same to patients for the control and prophylaxis of cardiovascular disorders.
Abstract:
The 1,2,3,4-oxatriazolium-5-olates of the formula I ##STR1## in which R.sup.1 denotes, for example, (C.sub.2 to C.sub.4)alkyl,R.sup.2 and R.sup.3 denotes (C.sub.1 to C.sub.4)alkyl have useful pharmacological properties.
Abstract:
Substituted 3-aminosydnone imines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes an alkylene chain;X denotes one of the groups --O-- or --S--;R.sup.1 denotes e.g. hydrogen;R.sup.2 denotes e.g. an alkyl group,are prepared by cyclization of a compound of the formula II ##STR2## and, if appropriate, subsequent acylation, and have useful pharmacological properties.
Abstract:
Optically active substituted 3-aminosydnonimines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, wherein R.sup.1 denotes, for example, the radical R.sup.3 (R.sup.4)N-,R.sup.2 denotes the radical 1-methoxyethyl (--CH(CH.sub.3)OCH.sub.3), acetoxy-phenyl-methyl (--CH(C.sub.6 H.sub.5)O--COCH.sub.3), 1-(ethoxycarbonyl)-ethoxy (--O--CH.sub.3)CO.sub.2 C.sub.2 H.sub.5),R.sup.3 denotes alkyl(C.sub.1 -C.sub.4) andR.sup.4 denotes for example alkyl(C.sub.1 -C.sub.4),possess valuable pharmaceutical properties.
Abstract translation:通式Ⅰ的光学活性的取代的3-氨基二氨基亚胺及其药学上可接受的酸加成盐,其中R1表示例如基团R3(R4)N-,R2表示基团1-甲氧基乙基(-CH( CH 3)OCH 3),乙酰氧基 - 苯基 - 甲基(-CH(C 6 H 5)O-COCH 3),1-(乙氧基羰基) - 乙氧基(-O-CH 3)CO 2 C 2 H 5),R 3表示烷基(C 1 -C 4) 烷基(C1-C4)具有有价值的药物性质。
Abstract:
Optically active substituted 1,4-dihydropyridines of the formula I having calcium antogonistic properties: ##STR1## wherein R denotes alkyl with 1 to 5 C atoms, alkoxy-alkyl with 1 to 4 C atoms, in the alkoxy part and 2 to 4 C atoms in the alkyl part, dialkylaminioalkyl with a total of 3 to 6 C atoms each of the alkyl groups as substituents on the amino group having 1 to 3 C atoms, or --CH(CH.sub.3)CO.sub.2 R.sup.5 in the optically active (R)-forms,R.sup.1 denotes phenyl which is monosubstituted by cyano, nitro or chlorine or is disubstituted by chlorine, R.sup.2 denotes oxadiazolyl, or an oxadiaxolyl which is substituted by methyl, ethyl, i-propyl, tert.-butyl, benzyl, methylthio, i-propylthio, aminocarbonylthio or methoxymethyl,R.sup.5 denotes alkyl with 1 to 4 C atoms, and acid-addition salts thereof, and acid addition salts thereof.
Abstract:
Organic nitrates, processes for their preparation and their use in the treatment of vascular diseases and in particular in the treatment of angina.The said nitrates correspond to the following formula I:R--CO--(A).sub.n --Y--B (I)in which:R represents, in particular, a sulphur-containing radical and a sulphur-containing amino acid residue; A represents, in particular, a CH.sub.2 group or a substituted amino acid; n is 0 or 1 or greater than 1; Y represents an oxygen atom or an NH group and B represents, in particular, a 1,4:3,6-dianhydro hexitol mononitrate radical, an itol nitrate radical or an inositol radical.The said organic nitrates are prepared by reacting:I. either a thio acid of the type R--COOH, in which R has the same meaning as above, with a derivative of formula II: (A).sub.n --Y--B, in which A, Y, B and n have the same meaning as above,II. or a derivative of formula III: R--CO--(A).sub.n, in which R, A and n have the same meaning as above, with a derivative of formula Y--B, in which Y and B have the same meaning as above, in an appropriate solvent and under non-epimerising conditions.